May 01, 2025

DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths

A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halve...

The ASCO Post

April 30, 2025

AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash

Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial re...

The ASCO Post

April 30, 2025

AACR 2025: AI-Driven Model For Identifying Cancer Cachexia

Use of a multimodal deep learning–based model led to more accurate and earlier identifications of cancer cachexia than standard clinical and radiological observations, according to findings presented ...

The ASCO Post

April 28, 2025

AACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors

PD-1 blockade with the PD-1 inhibitor dostarlimab-gxly induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair–deficient cancers, accordin...

The ASCO Post

April 28, 2025

AACR 2025: Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer

Interim results from the VICTORI study, which were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, showed that an ultrasensitive circulating tumor DNA (ctDNA)-bas...

The ASCO Post

April 24, 2025

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer

The FDA approved the combination of a PD-1 inhibitor and a CTLA-4 inhibitor for patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer ...

The ASCO Post

April 23, 2025

Benefits of Walnut Consumption: Curbing Inflammation, Colorectal Cancer Risk

Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer.

The ASCO Post

April 09, 2025

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer

The FDA approved the combination of a PD-1 inhibitor and a CTLA-4 inhibitor for patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer ...

The ASCO Post

February 15, 2024

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Circulating tumor DNA may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from receiving adjuvant chemotherapy. The re...

The ASCO Post